PKR and eIF2α Pathway Modulation for Selective RAN Translation Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The mechanism of repeat-associated non-ATG (RAN) translation has not been fully understood, leading to unaddressed protein toxicity in diseases such as Huntington's disease and amyotrophic lateral sclerosis, despite the association of RAN proteins with these conditions.
Innovation Solution
Inhibition of eukaryotic initiation factor 2-alpha (eIF2α) phosphorylation and/or expression of alternative eIF2A, or inhibition of Protein Kinase R (PKR), using agents like eIF2 modulating agents or PKR inhibitors, to reduce RAN protein translation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If RAN translation is inhibited by targeting eIF2α phosphorylation or PKR pathway, then RAN protein accumulation is reduced, but normal translation initiation may be affected
Solution Approach 1:
The patent applies local quality by using repeat-containing RNAs as specific substrates that selectively recruit and activate PKR only at sites of repeat expansion. This localized PKR activation leads to targeted eIF2α phosphorylation specifically associated with RAN translation, while leaving general translation initiation factors and pathways relatively unaffected. The repeat RNA structure itself creates a localized zone of translational regulation that spares normal protein synthesis.
Solution Approach 2:
The patent employs repeat-containing RNAs as intermediary molecules that mediate between the repeat expansion pathology and the PKR/eIF2α pathway. These RNAs act as selective intermediaries that bridge the pathological repeat sequences and the translational machinery, allowing PKR to be activated specifically by abnormal repeat RNAs rather than normal mRNAs. This intermediary mechanism enables selective inhibition of RAN translation while preserving normal translation through the use of RNA-mediated specificity.
2Reliability
If eIF2 modulating agents or PKR inhibitors are used to reduce RAN protein translation, then therapeutic effect is achieved, but off-target effects on global translation may occur
Solution Approach 1:
The patent inverts the conventional approach by instead of directly inhibiting PKR or eIF2α with small molecule inhibitors that would affect all translation, it activates PKR specifically through repeat-containing RNAs. This inverted strategy uses activation rather than inhibition, and uses the pathological RNA itself as the activating agent, thereby turning the pathology into the selective trigger for therapeutic action. The repeat RNA acts as a molecular key that opens the PKR pathway only where needed.
Solution Approach 2:
The patent applies self-service by allowing the repeat-containing RNAs to autonomously activate PKR and initiate the eIF2α phosphorylation cascade at sites of repeat expansion. The pathological RNA molecules themselves serve as the activating ligands, requiring no external drugs or inhibitors. The cell's own translational machinery and stress response pathways are harnessed to automatically respond to and suppress RAN translation at the site of repeat expansion, making the therapeutic mechanism self-regulating and highly specific.
Data Source
AI summary
Methods and compositions for modulating repeat non-ATG protein (RAN protein) translation are provided. In some aspects, the disclosure provides methods of inhibiting RAN protein translation by contacting a cell with an effective amount of an inhibitor of eIF2 phosphorylation or an inhibitor of protein kinase R (PKR). In some embodiments, methods described by the disclosure are useful for treating diseases associated with RAN protein translation, such as certain neurodegenerative diseases.